| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
135,731 |
125,766 |
$15.52M |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
67,375 |
63,555 |
$8.34M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
48,001 |
44,773 |
$5.68M |
| S9083 |
Global fee urgent care centers |
20,288 |
18,216 |
$2.66M |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
14,377 |
14,085 |
$1.99M |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
15,116 |
14,643 |
$1.88M |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
7,415 |
6,973 |
$949K |
| 99050 |
|
126,910 |
121,744 |
$902K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
60,391 |
30,056 |
$382K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
22,383 |
21,807 |
$222K |
| 99072 |
|
47,564 |
44,484 |
$114K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
53,245 |
50,400 |
$85K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
55,826 |
52,736 |
$31K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
534 |
453 |
$18K |
| 91300 |
|
997 |
600 |
$9K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
575 |
544 |
$9K |
| 99421 |
|
467 |
443 |
$6K |
| 0002A |
|
587 |
393 |
$6K |
| 0001A |
|
493 |
357 |
$5K |
| S0119 |
Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) |
1,265 |
1,074 |
$3K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
4,175 |
3,704 |
$3K |
| 0071A |
|
191 |
137 |
$2K |
| 87807 |
|
4,340 |
4,147 |
$2K |
| 69210 |
|
1,080 |
988 |
$2K |
| 0072A |
|
144 |
97 |
$2K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
2,651 |
2,276 |
$2K |
| 99000 |
|
1,350 |
1,246 |
$910.01 |
| 81002 |
|
1,809 |
1,694 |
$753.45 |
| 87428 |
|
581 |
444 |
$526.03 |
| 0012A |
|
30 |
28 |
$400.00 |
| 0011A |
|
30 |
28 |
$280.00 |
| 69209 |
|
47 |
41 |
$255.13 |
| J7510 |
Prednisolone oral, per 5 mg |
4,215 |
3,792 |
$246.39 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
437 |
405 |
$136.20 |
| 71046 |
Radiologic examination, chest; 2 views |
507 |
490 |
$77.52 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
3,037 |
2,685 |
$71.81 |
| 91301 |
|
39 |
38 |
$40.00 |
| 94664 |
|
599 |
548 |
$22.72 |
| 73140 |
|
24 |
24 |
$19.19 |
| 86308 |
|
77 |
66 |
$9.00 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
676 |
616 |
$8.96 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
627 |
553 |
$0.00 |
| 99001 |
|
461 |
453 |
$0.00 |
| 73630 |
|
13 |
13 |
$0.00 |
| 73610 |
|
13 |
12 |
$0.00 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
202 |
144 |
$0.00 |
| 91307 |
|
300 |
197 |
$0.00 |
| 87081 |
|
29 |
28 |
$0.00 |
| A6453 |
Self-adherent bandage, elastic, non-knitted/non-woven, width less than three inches, per yard |
131 |
111 |
$0.00 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
169 |
149 |
$0.00 |
| 36416 |
|
12 |
12 |
$0.00 |
| 87070 |
|
157 |
140 |
$0.00 |
| 36415 |
Collection of venous blood by venipuncture |
13 |
12 |
$0.00 |